GLP-1 Drugs May Carry Rare Risk of Vision Loss, Experts Call for Vigilance: Research
India: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual incretin therapies have transformed the treatment of type 2 diabetes and obesity, delivering significant benefits in glycemic control, weight loss, and cardiovascular health. However, a point-of-view article published in the Journal of the Association of Physicians of India has highlighted emerging concerns about potential vision-related adverse effects associated with these therapies and emphasized the need for careful monitoring in clinical practice.
The article was authored by Abhyuday Saxena from the Department of Ophthalmology, Dr. R. P. Centre, All India Institute of Medical Sciences, and Anupam Prakash from Lady Hardinge Medical College.
According to the authors, growing postmarketing evidence has linked GLP-1–based therapies, including semaglutide and tirzepatide, to certain ophthalmic adverse events. While these drugs continue to play an important role in managing metabolic diseases, recent pharmacovigilance analyses, cohort studies, and case reports have raised concerns regarding ocular safety.
Key takeaways from the article:
- GLP-1 receptor agonists and dual incretin therapies have significantly improved the management of diabetes and obesity.
- Emerging evidence suggests a possible association between these therapies and ophthalmic adverse events.
- Reported eye-related complications include early worsening of diabetic retinopathy and nonarteritic anterior ischemic optic neuropathy (NAION).
- NAION is a rare but potentially irreversible cause of sudden vision loss, particularly in adults over 50 years of age.
- Although the absolute risk is very low, regulatory agencies have identified NAION as a very rare adverse effect of semaglutide.
- Similar safety signals are being investigated for other GLP-1–based therapies, raising the possibility of a class effect.
- The association remains unproven, and a direct causal relationship has not yet been established.
- India's large population with diabetes and obesity means that even rare adverse events could have important public health implications.
The authors noted that several biological mechanisms have been proposed, including impaired blood flow to the optic nerve, sympathetic-mediated vascular changes, and rapid glucose reductions affecting vascular autoregulation. However, further research is needed to clarify these mechanisms and determine whether the observed associations are causal.
Given the increasing use of these therapies in India, the authors advocated a balanced approach that preserves their metabolic benefits while minimizing potential risks. They recommended baseline ophthalmic assessment for high-risk individuals, patient education regarding visual symptoms, prompt referral for eye evaluation when symptoms arise, stronger pharmacovigilance systems, and closer collaboration between endocrinologists and ophthalmologists.
The authors concluded that GLP-1–based therapies remain a major therapeutic advance, but ocular safety should become an integral part of prescribing practices. With newer agents such as retatrutide expected to enter clinical use in the near future, careful monitoring for vision-related adverse effects will be essential to ensure that improvements in metabolic health are not accompanied by preventable vision loss.
Reference:
Saxena A, Prakash A. Glucagon Agonist Therapies and Vision Loss: Balancing Promise with Prudence in India. J Assoc Physicians India 2026;74(6):94–96.
